For instance, NAD+ supplementation inhibited the PARP activity in astrocytes from patients and mice with non-alcoholic fatty liver disease (NAFLD), restored the glycolysis and mitochondrial function, and reduced oxidative stress [146,147]. The gene discussed is PARP1; the disease is metabolic dysfunction-associated steatotic liver disease.